Response rate and outcome after rituximab therapy
| . | Month +2 . | Month +6 . | Month +12 . |
|---|---|---|---|
| WAIHA 14/23 (60.9%) | OR 14/14 (100%) | SR 14/14 (100%) | SR 13/13 (100%) |
| CR 11 (78.6%) | CR 10 (71.4%) | CR 9 (69.2%) | |
| PR 3 (21.4%) | PR 4 (28.6%) | PR 4 (30.8%) | |
| NR 0 (0%) | NR 0 (0%) | NR 0 (0%) | |
| Relapse rate 0 (0%) | Relapse rate 0 (0%) | Relapse rate 0 (0%) | |
| CHD 9/23 (39.1%) | OR 5/9 (55.6%) | SR 7/9 (77.7%) | SR 3/6 (50%) |
| CR 4 (44.4%) | CR 4 (44.4%) | CR 1 (16.6%) | |
| PR 1 (11.2%) | PR 3 (33.3%) | PR 2 (33.3%) | |
| NR 4 (44.4%) | NR 1 (11.15%) | NR 0 (0%) | |
| Relapse rate 0 (0%) | Relapse rate 1 (11.15%) | Relapse rate 2 (33.3%) |
| . | Month +2 . | Month +6 . | Month +12 . |
|---|---|---|---|
| WAIHA 14/23 (60.9%) | OR 14/14 (100%) | SR 14/14 (100%) | SR 13/13 (100%) |
| CR 11 (78.6%) | CR 10 (71.4%) | CR 9 (69.2%) | |
| PR 3 (21.4%) | PR 4 (28.6%) | PR 4 (30.8%) | |
| NR 0 (0%) | NR 0 (0%) | NR 0 (0%) | |
| Relapse rate 0 (0%) | Relapse rate 0 (0%) | Relapse rate 0 (0%) | |
| CHD 9/23 (39.1%) | OR 5/9 (55.6%) | SR 7/9 (77.7%) | SR 3/6 (50%) |
| CR 4 (44.4%) | CR 4 (44.4%) | CR 1 (16.6%) | |
| PR 1 (11.2%) | PR 3 (33.3%) | PR 2 (33.3%) | |
| NR 4 (44.4%) | NR 1 (11.15%) | NR 0 (0%) | |
| Relapse rate 0 (0%) | Relapse rate 1 (11.15%) | Relapse rate 2 (33.3%) |
NR indicates no response.